OraSure Technologies (NASDAQ:OSUR) Hits New 52-Week Low at $8.01

OraSure Technologies, Inc. (NASDAQ:OSUR) reached a new 52-week low on Monday . The stock traded as low as $8.01 and last traded at $8.03, with a volume of 1429 shares trading hands. The stock had previously closed at $8.25.

Several research firms recently weighed in on OSUR. BidaskClub cut shares of OraSure Technologies from a “hold” rating to a “sell” rating in a research note on Thursday, July 18th. Canaccord Genuity lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating and set a $10.00 price target for the company. in a research report on Thursday, May 9th. Finally, Zacks Investment Research lowered shares of OraSure Technologies from a “hold” rating to a “sell” rating in a report on Tuesday, July 9th. Three research analysts have rated the stock with a sell rating and one has assigned a hold rating to the company’s stock. The stock presently has an average rating of “Sell” and a consensus price target of $10.00.

The stock has a market capitalization of $501.98 million, a P/E ratio of 16.08, a price-to-earnings-growth ratio of 2.87 and a beta of 1.19. The firm has a fifty day moving average of $8.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.56 and a current ratio of 7.52.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. The company had revenue of $30.12 million during the quarter, compared to analyst estimates of $29.66 million. OraSure Technologies had a net margin of 11.34% and a return on equity of 7.87%. The company’s revenue was down 28.3% on a year-over-year basis. During the same quarter last year, the business posted $0.07 earnings per share. As a group, analysts expect that OraSure Technologies, Inc. will post 0.23 earnings per share for the current year.

In other news, CFO Roberto Cuca acquired 10,000 shares of the company’s stock in a transaction dated Friday, May 10th. The stock was bought at an average price of $9.03 per share, with a total value of $90,300.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have bought 21,000 shares of company stock valued at $184,360. Company insiders own 1.70% of the company’s stock.

Several institutional investors have recently modified their holdings of OSUR. American Capital Management Inc. increased its holdings in shares of OraSure Technologies by 67.2% in the first quarter. American Capital Management Inc. now owns 2,876,592 shares of the medical instruments supplier’s stock valued at $32,074,000 after purchasing an additional 1,156,560 shares in the last quarter. Norges Bank acquired a new stake in shares of OraSure Technologies in the fourth quarter valued at approximately $8,099,000. Systematic Financial Management LP increased its holdings in shares of OraSure Technologies by 20.8% in the second quarter. Systematic Financial Management LP now owns 1,350,836 shares of the medical instruments supplier’s stock valued at $12,536,000 after purchasing an additional 232,240 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of OraSure Technologies by 96.6% in the fourth quarter. Two Sigma Advisers LP now owns 162,720 shares of the medical instruments supplier’s stock valued at $1,901,000 after purchasing an additional 79,961 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of OraSure Technologies by 10.7% in the fourth quarter. Geode Capital Management LLC now owns 716,260 shares of the medical instruments supplier’s stock valued at $8,364,000 after purchasing an additional 69,347 shares in the last quarter. 91.55% of the stock is owned by institutional investors and hedge funds.

OraSure Technologies Company Profile (NASDAQ:OSUR)

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Story: Gap Up Stocks

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.